Active, not recruitingPhase 2NCT05077709
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
Studying Squamous cell carcinoma of head and neck
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- IO Biotech
- Principal Investigator
- Jonathan W Riess, MD, MScDivision of Hematology/Oncology, UC Davis Comprehensive Cancer Center
- Intervention
- IO102-IO103 in combination with pembrolizumab(drug)
- Enrollment
- 63 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2024
Study locations (21)
- City of Hope, Duarte, California, United States
- UC Davis Cancer Center, Sacramento, California, United States
- University of California San Diego, San Diego, California, United States
- Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
- Montefiore Medical Center, The Bronx, New York, United States
- University of Toledo Medical Center, Toledo, Ohio, United States
- Oregon Health & Science University, Portland, Oregon, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Virginia Cancer Specialists, Fairfax, Virginia, United States
- Hospital Vall d'Hebron, Barcelona, Spain
- Institut Català d'Oncologia (ICO) Badalona (Catalan Institute of Oncology), Barcelona, Spain
- Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain
- Hospital Universitario Ramon y Cajal, Madrid, Spain
- Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- +6 more locations on ClinicalTrials.gov
Collaborators
Theradex · Almac · NeoGenomics · Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05077709 on ClinicalTrials.govOther trials for Squamous cell carcinoma of head and neck
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07333274Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE3NCT07026474Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCUniversität des Saarlandes
- RECRUITINGPHASE1NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNormunity AccelCo, Inc.
- RECRUITINGNANCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled TrialTobias Todsen
- RECRUITINGNANCT07180901Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck CancerCentre hospitalier de l'Université de Montréal (CHUM)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415Local Injection Methylene Blue Combined With Radiation in HNSCC PatientsChina Medical University Hospital
- RECRUITINGPHASE2NCT07088211Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- RECRUITINGPHASE2NCT07040956A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.West China Hospital
See all trials for Squamous cell carcinoma of head and neck →